Streetbeat News

PBLA

Panbela Therapeutics Inc.

http://www.sunbiopharma.com/

CEO

Michael Cullen

Open

0.32

Mkt cap

1.6M

Volume

6.3K

High

0.33

P/E Ratio

N/A

52-wk high

38.00

Low

0.32

Div yield

N/A

52-wk low

0.30

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biomerica, Cingulate, Arcutis Biotherapeutics, Panbela Therapeutics, NRX Pharmaceuticals, and Alaunos Therapeutics saw their shares rise by 54.5%, 33.33%, 31.14%, 30.54%, 30.08%, and 29.89% respectively. Conversely, Minerva Surgical, Checkpoint Therapeutics, Structure Therapeutics, Lantheus Holdings, Ainos, and Blue Water Biotech faced declines of 52.5%, 50.31%, 45.24%, 18.8%, 18.08%, and 16.08% respectively.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:07 pm

In Monday's after-market session, several healthcare stocks experienced significant movements. Jin Medical International (ZJYL) saw a substantial increase of 72.5%, while NRX Pharmaceuticals (NRXP) led the losers with a 12.1% decrease. Other notable gainers include Panbela Therapeutics (PBLA), IN8bio (INAB), Reviva Pharmaceuticals (RVPH), CNS Pharma (CNSP), and Nexalin Technology (NXL). On the losing side, bluebird bio (BLUE), Senti Biosciences (SNTI), Motus GI Holdings (MOTS), Zura Bio (ZURA), and BioAtla (BCAB) also saw declines.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 9:31 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. Invivyd (IVVD) saw a sharp increase of 157.7%, while Panbela Therapeutics (PBLA) and Biomerica (BMRA) also posted substantial gains. Conversely, Cara Therapeutics (CARA), Checkpoint Therapeutics (CKPT), and Minerva Surgical (UTRS) were among the notable losers, with their stock prices falling significantly.

Portfolio Pulse from Benzinga Insights

December 18, 2023 | 5:32 pm

Panbela Therapeutics' stock is trading higher following the FDA approval of eflornithine, which was part of the assets divested by Panbela to US WorldMeds for their pediatric neuroblastoma program.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 4:11 pm

Roth MKM analyst Jonathan Aschoff has reiterated a Buy rating on Panbela Therapeutics (NASDAQ:PBLA) and maintained a $25 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 3:41 pm

Panbela Therapeutics Inc (NASDAQ:PBLA) stock rose by 9.7% to $0.50 after announcing FDA approval of eflornithine, a drug they divested to US WorldMeds, for high-risk neuroblastoma patients. Panbela may receive up to $9.5 million based on milestones from USWM. The approval is the first for a polyamine targeted therapy in cancer, with potential implications for other cancers. PBLA's 52-week range is $0.45 to $225.71.

Portfolio Pulse from Henry Khederian

December 18, 2023 | 3:18 pm

Panbela Therapeutics announced that US WorldMeds has received FDA approval for its New Drug Application (NDA) for Eflornithine, which is intended to treat pediatric neuroblastoma.

Portfolio Pulse from Benzinga Newsdesk

December 18, 2023 | 1:17 pm

The article discusses notable value stocks in the healthcare sector, highlighting their low price-to-earnings (P/E) multiples, which suggest they may be undervalued. The stocks mentioned are Cross Country Healthcare (CCRN), Nuwellis (NUWE), First Wave BioPharma (FWBI), Voyager Therapeutics (VYGR), and Panbela Therapeutics (PBLA). The article also provides recent earnings per share data for these companies, indicating their financial performance.

Portfolio Pulse from Benzinga Insights

December 11, 2023 | 2:43 pm

In Monday's pre-market session, several healthcare stocks experienced significant movements. EyePoint Pharmaceuticals (EYPT) saw a dramatic increase of 378.8%, while Alterity Therapeutics (ATHE) and Lucy Scientific Discovery (LSDI) also posted substantial gains. On the downside, NexImmune (NEXI) and Panbela Therapeutics (PBLA) experienced notable declines, along with other companies such as Sana Biotechnology (SANA) and Vivos Therapeutics (VVOS).

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 1:06 pm

Hawaiian Airlines (NASDAQ:HA) shares surged over 180% in pre-market trading following the announcement that Alaska Air Group, Inc. (NYSE:ALK) plans to acquire the company for $1.9 billion. The merger is expected to expand domestic and international options for customers. Other stocks showed significant movement in pre-market trading, with notable gainers including Hut 8 Mining Corp (NASDAQ:HUT) and Bit Brother Limited (NASDAQ:BETS), and losers such as NLS Pharmaceutics AG (NASDAQ:NLSP) and Panbela Therapeutics, Inc. (NASDAQ:PBLA).

Portfolio Pulse from Lisa Levin

December 04, 2023 | 1:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.